Assorted news from the last week:
In celebration of International Childhood Cancer Awareness Day on February 15, the World Health Organization released a suite of tools to help countries improve diagnosis and treatment of cancer among children. The package includes a “how-to” guide for policy-makers, cancer control programme managers and hospital managers; an assessment tool to inform implementation; and a multilingual online portal for information-sharing.
Currently, categorizing clinical trials as ‘negative’ is based solely on the main outcome of the trial without taking into account whether there are other outcomes that could be positive for patients or other reasons for this result. This issue is particularly important in rare diseases where there are so few treatments available. This paper proposes a different way of categorizing clinical trials.
Day One Biopharmaceuticals began last year with a mission to tackle childhood cancers. This week, the company raised $130 million with series B financing. The funds will bankroll development and launch plans for its lead program, a pan-RAF inhibitor it’s developing for children with brain cancer, as well as its search for new drug programs to pick up.
New, distinctive Kansas license plates could raise awareness, and in some cases money for childhood cancer cancer research, military service veterans, educators and a historically Black sorority.
Upcoming Webinars and Online Opportunities:
Webinar panel discussion onThursday, February 18 at noon ET: NCRI-ICRP: Exploring global partnerships in cancer research funding. The presenters will explain more about the benefits of collaboration between international cancer research funders. You will hear from a selection of organizations who have set up successful international collaborative funding opportunities to address gaps in cancer research, including Cancer Research UK, US National Cancer Institute Center for Global Health, Worldwide Cancer Research, Cancer Australia and the World Cancer Research Fund International. The panel will discuss the impact of COVID-19, opportunities for future collaborations, and discuss best practice in establishing international collaborative funding streams.